Treatment of Central Serous Chorioretinopathy by Beta-blocking Agents

Czech version

Authors: O. Chrapek; K. Špačková; J. Řehák
Authors‘ workplace: Oční klinika FN a LF UP, Olomouc, přednosta doc. MUDr. Jiří Řehák, CSc.
Published in: Čes. a slov. Oftal., , 2002, No. 6, p. 382-386
Category:

Overview

On a group of 13 eyes the authors evaluate their experience with medicamentoustreatment of central serous chorioretinopathy. For treatment they used the nonselectivebeta-blocker Trimepranol, 2x5mg/day. They found that in 11 eyes, in84.6 % cases, adherence of the ablated neuroepithelium of the macula occurredlatest within four months of treatment, in two eyes (15.4 %) this therapeutic dosedid not lead to remission of the disease even after four months of treatment andthe condition was evaluated as failure of treatment. The authors conclude thata therapeutic dose of Trimepranol of 2x5mg/day is not a reliable therapeuticsolution of central serous chorioretinopathy.

Key words:
central serous chorioretinopathy - beta-blockers

Full text is not available online.

If interested in a scan of this journal, contact NTO ČLS JEP.

Labels

Ophthalmology

Combined Hamartoma of the Retina and Retinal Pigment Epithelium

First Experiences with the Implantation of Miniaturized Intraocular Teleskop(IMT) of Age-related Macular Degeneration (ARMD) - dry Form

Effect of TLT Absorption Glasses on the Progress of Myopia in Children

Erosio Corneae Recidivans - Current State of Treatment

Giant Cell Angofibroma of the Lower Eyelids

Assortative Mating for Refractive Errors of the Eyes

Article was published in

Czech and Slovak Ophthalmology

2002 Issue 6